The new funding will help the cluster build on initial milestones and to prepare for clinical applications, particularly in cancer.

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

The operating margin decreased 180 basis points year over year to 18.1% in the fourth quarter, principally driven by three ...